Eve Wittenberg1, Jeremy W Bray2, Brandon Aden3, Achamyeleh Gebremariam4, Bohdan Nosyk5,6, Bruce R Schackman3. 1. Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 2. Department of Economics, University of North Carolina at Greensboro, Greensboro, NC, USA. 3. Department of Healthcare Policy and Research and Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 4. CH Mott Children's Hospital, University of Michigan, Ann Arbor, MI, USA. 5. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada. 6. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Abstract
AIMS: To understand how the general public views the quality of life effects of opioid misuse and opioid use disorder on an individual and his/her spouse, measured in terms used in economic evaluations. DESIGN: Cross-sectional internet survey of a US population-representative respondent panel conducted December 2013-January 2014. SETTING: United States. PARTICIPANTS: A total of 2054 randomly selected adults; 51.1% male (before weighting). MEASUREMENTS: Mean (95% confidence interval) and median health 'utility' for six opioid misuse and treatment outcomes: active injection misuse; active prescription misuse; methadone maintenance therapy at initiation and when stabilized in treatment; and buprenorphine therapy at initiation and when stabilized. Utility is a numerical representation of health-related quality of life used in economic evaluations to 'adjust' estimated survival to include peoples' preferences for health states. Utilities are determined by surveying the general population to estimate the value they assign to particular health states on a scale where 0 = the value of being dead and 1.0 = the value of being in perfect health. Spouse spillover utility is assigned to a spouse of an individual who is in a particular health state. FINDINGS: Mean individual utility ranged from 0.574 [95% confidence interval (CI) = 0.538, 0.611] for active injection opioid misuse to 0.766 for stabilized buprenorphine therapy (95% CI = 0.738, 0.795), with other states in between. Female respondents assigned higher utility to the active prescription misuse and buprenorphine therapy at initiation states than did males (P < 0.05); all other states did not differ by respondent gender. Mean spousal utilities were significantly lower than 1.0 but mostly higher than individual utility, and were similar between male and female respondents. CONCLUSIONS: In the opinion of the US public, injection opioid misuse results in worse health-related quality of life than prescription misuse, and methadone therapy results in worse health-related quality of life than buprenorphine therapy. Spouses are negatively affected by their partner's opioid misuse and early treatment.
AIMS: To understand how the general public views the quality of life effects of opioid misuse and opioid use disorder on an individual and his/her spouse, measured in terms used in economic evaluations. DESIGN: Cross-sectional internet survey of a US population-representative respondent panel conducted December 2013-January 2014. SETTING: United States. PARTICIPANTS: A total of 2054 randomly selected adults; 51.1% male (before weighting). MEASUREMENTS: Mean (95% confidence interval) and median health 'utility' for six opioid misuse and treatment outcomes: active injection misuse; active prescription misuse; methadone maintenance therapy at initiation and when stabilized in treatment; and buprenorphine therapy at initiation and when stabilized. Utility is a numerical representation of health-related quality of life used in economic evaluations to 'adjust' estimated survival to include peoples' preferences for health states. Utilities are determined by surveying the general population to estimate the value they assign to particular health states on a scale where 0 = the value of being dead and 1.0 = the value of being in perfect health. Spouse spillover utility is assigned to a spouse of an individual who is in a particular health state. FINDINGS: Mean individual utility ranged from 0.574 [95% confidence interval (CI) = 0.538, 0.611] for active injection opioid misuse to 0.766 for stabilized buprenorphine therapy (95% CI = 0.738, 0.795), with other states in between. Female respondents assigned higher utility to the active prescription misuse and buprenorphine therapy at initiation states than did males (P < 0.05); all other states did not differ by respondent gender. Mean spousal utilities were significantly lower than 1.0 but mostly higher than individual utility, and were similar between male and female respondents. CONCLUSIONS: In the opinion of the US public, injection opioid misuse results in worse health-related quality of life than prescription misuse, and methadone therapy results in worse health-related quality of life than buprenorphine therapy. Spouses are negatively affected by their partner's opioid misuse and early treatment.
Authors: Holger J Schünemann; Lauren Griffith; Roman Jaeschke; Roger Goldstein; David Stubbing; Gordon H Guyatt Journal: J Clin Epidemiol Date: 2003-12 Impact factor: 6.437
Authors: Bohdan Nosyk; Huiyung Sun; Daphne P Guh; Eugenia Oviedo-Joekes; David C Marsh; Suzanne Brissette; Martin T Schechter; Aslam H Anis Journal: J Clin Epidemiol Date: 2010-03-17 Impact factor: 6.437
Authors: M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor Journal: Health Technol Assess Date: 2007-03 Impact factor: 4.014
Authors: Andrew Rosenblum; Herman Joseph; Chunki Fong; Steven Kipnis; Charles Cleland; Russell K Portenoy Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Susan H Busch; David A Fiellin; Marek C Chawarski; Patricia H Owens; Michael V Pantalon; Kathryn Hawk; Steven L Bernstein; Patrick G O'Connor; Gail D'Onofrio Journal: Addiction Date: 2017-08-16 Impact factor: 6.526
Authors: Ali Jalali; Danielle A Ryan; Philip J Jeng; Kathryn E McCollister; Jared A Leff; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman; Sean M Murphy Journal: Drug Alcohol Depend Date: 2020-08-05 Impact factor: 4.492
Authors: Eve Wittenberg; Carolina Barbosa; Riley Hein; Emma Hudson; Benjamin Thornburg; Jeremy W Bray Journal: Drug Alcohol Depend Date: 2021-01-29 Impact factor: 4.492
Authors: Courtney A Polenick; Diarratou Kaba; Annie N Zhou; Benjamin H Han; Brandi Parker Cotton Journal: Drug Alcohol Depend Date: 2020-11-13 Impact factor: 4.492
Authors: Sarah Gutkind; Bruce R Schackman; Jake R Morgan; Jared A Leff; Linda Agyemang; Sean M Murphy; Matthew J Akiyama; Brianna L Norton; Alain H Litwin; Benjamin P Linas Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 20.999
Authors: Joshua A Barocas; Jake R Morgan; David A Fiellin; Bruce R Schackman; Golnaz Eftekhari Yazdi; Michael D Stein; Kenneth A Freedberg; Benjamin P Linas Journal: Int J Drug Policy Date: 2019-05-10